Crystallization of Cyclophosphamide Monohydrate During Lyophilization
-
Add time:07/14/2019 Source:sciencedirect.com
The purpose of this study was to investigate the phase behavior of cyclophosphamide (CPA) during various stages of lyophilization, with special emphasis on obtaining crystalline CPA monohydrate (CPA-MH) in the lyophilized product. Subambient differential scanning calorimetry and low-temperature X-ray diffractometry (LTXRD) were used to study the phase behavior of CPA solution (3.7% w/v). In situ lyophilization in LTXRD chamber was used to monitor the phase transitions occurring during the drying stages. Finally, the implications of these findings were confirmed by freeze-drying the aqueous solution in a laboratory-scale freeze-dryer. The results suggested that CPA remains amorphous during freeze concentration, with a Tg' of −50°C. However, its crystallization as CPA-MH can be induced by annealing the frozen solution between −5°C and −10°C. In situ lyophilization in LTXRD showed that the CPA-MH crystallized during annealing, rapidly dehydrated during primary drying, thereby causing structural collapse. The dehydration of CPA-MH can be prevented by lowering the escaping tendency of water molecules from the crystal lattice of CPA-MH by maintaining the chamber pressure to 300, 400, or 500 mTorr. This study highlights the relationship of process parameters used during lyophilization with the solid form of lyophilized CPA.
We also recommend Trading Suppliers and Manufacturers of CyclophosphaMide IMpurity D (cas 45164-26-9). Pls Click Website Link as below: cas 45164-26-9 suppliers
Prev:Antihypertensive and cardioprotective effects of new compound 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril)
Next:Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product07/22/2019
- Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impurities07/20/2019
- Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography–mass spectrometry07/21/2019
- Guidelines and pharmacopoeial standards for pharmaceutical impurities: Overview and critical assessment07/19/2019
- Degradation of cyclophosphamide and 5-fluorouracil by UV and simulated sunlight treatments: Assessment of the enhancement of the biodegradability and toxicity07/18/2019
- Competitive binding of anticancer drugs 5-fluorouracil and cyclophosphamide with serum albumin: Calorimetric insights07/17/2019
- Determination of the impurities in drug products containing montelukast and in silico/in vitro genotoxicological assessments of sulfoxide impurity07/16/2019
- Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma07/15/2019


